OnabotulinumtoxinA for trigeminal neuralgia: A review of the available data

Pedro A. Kowacs; Marco A.T. Utiumi; Fábio A. Nascimento; Elcio J. Piovesan; Helio A.G. Teive

doi:10.1590/0004-282X20150109

OnabotulinumtoxinA for trigeminal neuralgia: A review of the available data

Translated title of the contribution: OnabotulinumtoxinA for trigeminal neuralgia: A review of the available data

Pedro A. Kowacs, Marco A.T. Utiumi, Fábio A. Nascimento, Elcio J. Piovesan, Helio A.G. Teive

Section of Adult Epilepsy

Research output: Contribution to journal › Review article › peer-review

14 Scopus citations

Abstract

Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN.

Translated title of the contribution	OnabotulinumtoxinA for trigeminal neuralgia: A review of the available data
Original language	English
Pages (from-to)	877-884
Number of pages	8
Journal	Arquivos de Neuro-Psiquiatria
Volume	73
Issue number	10
DOIs	https://doi.org/10.1590/0004-282X20150109
State	Published - Oct 2015

Keywords

Botulinum neurotoxin type A
Botulinum-A toxin
Neuropathic pain
OnabotulinumtoxinA
Trigeminal neuralgia

Access to Document

10.1590/0004-282X20150109

Cite this

@article{14611c68deb54b9cab4ee4920e4ddd37,

title = "OnabotulinumtoxinA for trigeminal neuralgia: A review of the available data",

abstract = "Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN.",

keywords = "Botulinum neurotoxin type A, Botulinum-A toxin, Neuropathic pain, OnabotulinumtoxinA, Trigeminal neuralgia",

author = "Kowacs, {Pedro A.} and Utiumi, {Marco A.T.} and Nascimento, {F{\'a}bio A.} and Piovesan, {Elcio J.} and Teive, {Helio A.G.}",

year = "2015",

month = oct,

doi = "10.1590/0004-282X20150109",

language = "English",

volume = "73",

pages = "877--884",

journal = "Arquivos de Neuro-Psiquiatria",

issn = "0004-282X",

number = "10",

}

TY - JOUR

T1 - OnabotulinumtoxinA for trigeminal neuralgia

T2 - A review of the available data

AU - Kowacs, Pedro A.

AU - Utiumi, Marco A.T.

AU - Nascimento, Fábio A.

AU - Piovesan, Elcio J.

AU - Teive, Helio A.G.

PY - 2015/10

Y1 - 2015/10

N2 - Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN.

AB - Trigeminal neuralgia (TN) patients may develop side effects from centrally acting drugs, have contraindications for neurosurgical procedures, or experience relapse during conventional therapies. OnabotulinumtoxinA (BoNT/A) has been reported to be effective for TN, although this finding has been challenged. An overview of the available evidence based on a narrative/qualitative analysis of the literature is presented. About 90% of patients who receive BoNT/A show an improvement, a higher figure than that reported for the placebo effect of BoNT/A for other headaches. Tolerability of BoNT/A is good, and its few side-effects are transient. The articles reviewed were mainly case reports, case series and open-label trials; however, randomized controlled trials have endorsed the efficacy of BoNT/A for TN. This evidence, together with a better understanding of the analgesic mechanisms of BoNT/A and its proven efficacy in treating other pain syndromes, supports the use of this toxin as a therapeutic option for TN.

KW - Botulinum neurotoxin type A

KW - Botulinum-A toxin

KW - Neuropathic pain

KW - OnabotulinumtoxinA

KW - Trigeminal neuralgia

UR - http://www.scopus.com/inward/record.url?scp=84943808649&partnerID=8YFLogxK

U2 - 10.1590/0004-282X20150109

DO - 10.1590/0004-282X20150109

M3 - Review article

C2 - 26291995

AN - SCOPUS:84943808649

SN - 0004-282X

VL - 73

SP - 877

EP - 884

JO - Arquivos de Neuro-Psiquiatria

JF - Arquivos de Neuro-Psiquiatria

IS - 10

ER -

OnabotulinumtoxinA for trigeminal neuralgia: A review of the available data

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this